Verve Therapeutics is considering a half-dozen candidate genes that could be edited with the CRISPR technique in order to sharply reduce a patient’s levels of cholesterol or triglycerides.
This episode features exclusive access with Omar Khan and Coach Tomlin at Pro Days, Pittsburgh native and scout Jim Ward, and a Kicking Clinic in…
Eli Lilly reported Wednesday that the GLP-1 drug cut breathing interruptions in obese or overweight patients experiencing the condition.
Eli Lilly reported Wednesday that the GLP-1 drug cut breathing interruptions in obese or overweight patients experiencing the condition.
Eli Lilly reported Wednesday that the GLP-1 drug cut breathing interruptions in obese or overweight patients experiencing the condition.
Eli Lilly reported Wednesday that the GLP-1 drug cut breathing interruptions in obese or overweight patients experiencing the condition.
A drug in development as a weight loss treatment succeeded in a Phase 2 study in a serious liver condition, as the competition in the…
A drug in development as a weight loss treatment succeeded in a Phase 2 study in a serious liver condition, as the competition in the…
The drug industry officially has two new heavyweights. For the first time, Regeneron and Vertex have crossed the $100 billion market cap threshold. They join…
Gene editing’s therapeutic application has transitioned from hypothetical to reality, marked by the recent approval of a CRISPR-based therapy for sickle cell and beta thalassemia. |…
Newly named partner Anthony Philippakis and managing partner Krishna Yeshwant spoke with BioPharma Dive about biotech’s newfound optimism and their investing “North Star.”
